Levosimendan: Current status and future prospects

Current Opinion in Anaesthesiology

Volumn 21, Issue 1, 2008, Pages 78-84

  Archan, Sylvia ^a   Toller, Wolfgang ^a,b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY HOSPITAL GRAZ   (Austria)

Author keywords

Calcium sensitizer; Cardiac surgery; Heart failure; Levosimendan; Myocardial ischemia; Perioperative

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM SENSITIZER; DIURETIC AGENT; DOBUTAMINE; INOTROPIC AGENT; LEVOSIMENDAN; MILRINONE; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; PHOSPHODIESTERASE III INHIBITOR; PROSTAGLANDIN E1; VASODILATOR AGENT;

ADD ON THERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG METABOLISM; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; NONHUMAN; OPTIMAL DRUG DOSE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT OUTCOME;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; CARDIOTONIC AGENTS; HEART FAILURE; HUMANS; HYDRAZONES; POSTOPERATIVE COMPLICATIONS; PYRIDAZINES; SHOCK, SEPTIC; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 38149048418     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e3282f357a5     Document Type: Review

References (76)

1. Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study. Eur Heart J 2004; 25:1614-1619.
2. The Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of Cardiology. Increasing awareness and improving the management of heart failure in Europe: the IMPROVEMENT of HF initiative. Eur J Heart Fail 1999; 1:139-144.
3. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26:384-416.
4. Hernandez AF, Whellan DJ, Stroud S, et al. Outcomes in heart failure patients after major noncardiac surgery. J Am Coll Cardiol 2004; 44:1446-1453.
5. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005; 293:1900-1905.
6. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111:1487-1491.
7. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007; 297:1883-1891. In this large, randomized, double-blind trial comparing the efficacy and safety of intravenous levosimendan or dobutamine in 1327 patients hospitalized with acute decompensated heart failure levosimendan did not significantly reduce all-cause mortality at 180 days or affect any secondary clinical outcomes.
8. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006; 296:2217-2226.
9. Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure: a meta-regression analysis. Eur J Heart Fail 2002; 4:515-529.
10. Burger AJ, Horton DP, LeJemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002; 144:1102-1108.
11. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003; 41:997-1003.
12. Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 2006; 104:556-569.
13. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000; 102:2222-2227.
14. Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000; 36:1903-1912.
15. Hasenfuss G, Pieske B, Castell M, et al. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998; 98:2141-2147.
16. Givertz MM, Andreou C, Conrad CH, Colucci WS. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships. Circulation 2007; 115:1218-1224. This study demonstrated that the positive inotropic and lusitropic effects of levosimendan in humans with left ventricular dysfunction were not heart-rate dependent. In addition, levosimendan did not alter the slope of the force-frequency or relaxation-frequency relationship.
17. + channel in rat arterial myocytes. Eur J Pharmacol 1997; 333:249-259.
18. Michaels AD, McKeown B, Kostal M, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 2005; 111:1504-1509.
19. Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther 1999; 288:316-325.
20. Pagel PS, Hettrick DA, Warltier DC. Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br J Pharmacol 1996; 119:609-615.
21. ATP channels. Anesth Analg 2000; 90:5-11.
22. Jamali IN, Kersten JR, Pagel PS, et al. Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg 1997; 85:23-29.
23. Duygu H, Ozerkan F, Nalbantgil S, et al. Effect of levosimendan on E/E′ ratio in patients with ischemic heart failure. Int J Cardiol 2007; 19 Oct [Epub ahead of print]. Levosimendan caused a greater reduction of E/E′ ratio, a noninvasive, pulse-wave and tissue Doppler echocardiographic indicator of left ventricular filling pressure, than dobutamine in acute systolic left heart failure.
24. Adamopoulos S, Parissis JT, Iliodromitis EK, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006; 98:102-106.
25. Parissis JT, Adamopoulos S, Farmakis D, et al. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart 2006; 92:1768-1772.
26. Trikas A, Antoniades C, Latsios G, et al. Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. Eur J Heart Fail 2006; 8:804-809.
27. Antila S, Kivikko M, Lehtonen L, et al. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. Br J Clin Pharmacol 2004; 57:412-415.
28. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003; 107:81-86.
29. Lilleberg J, Laine M, Palkama T, et al. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail 2007; 9:75-82. In this double-blind, parallel group study in 22 patients with NYHA II to IV heart failure, left-ventricular ejection fraction under 35% and pulmonary capillary wedge pressure above 12 mmHg, a 24-h levosimendan infusion produced sustained hemodynamic effects and decreases of NT-proBNP for up to at least 1 week with maximal effects occurring after 1-3 days.
30. Packer M. REVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure [abstract]. Circulation 2005; 112:3363.
31. Puttonen J, Kantele S, Kivikko M, et al. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. Clin Pharmacokinet 2007; 46:235-246. This study investigated the pharmacokinetics of levosimendan and its metabolites OR-1896 and OR-1855 in patients with normal renal function, severe chronic renal failure and those with end-stage renal disease undergoing hemodialysis. While the parent drug was eliminated rapidly from the plasma after discontinuation of the infusion in all groups, the half-life of the metabolites was substantially prolonged in patients with compromised renal function. The authors therefore suggest that the dose of levosimendan should be reduced in patients with severe renal insufficiency.
32. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 23:1422-1432.
33. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360:196-202.
34. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVEII, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006; 8:105-110.
35. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA 2002; 287:628-640.
36. Mebazaa A, Cohen-Solal A, Kleber FX, et al. Levosimendan reduces mortality when compared with dobutamine in patients receiving beta blockers [abstract]. Eur J Heart Fail 2007; 6 (Suppl):95.
37. Cohen-Solal A, Mebazaa A, Thakkar R, et al. Levosimendan, compared to dobutamine, reduces mortality in patients with a history of heart failure [abstract]. Eur J Heart Fail 2007; 6 (Suppl):109.
38. Cavusoglu Y. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure. Expert Opin Pharmacother 2007; 8:665-677.
39. De Hert SG, Lorsomradee S, Cromheecke S, Van der Linden PJ. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg 2007; 104:766-773. In cardiac surgery patients with a low preoperative ejection fraction, stroke volume was better maintained with the combination of dobutamine with levosimendan started immediately after the release of the aortic crossclamp than with the combination of dobutamine with milrinone. Total dose, duration of inotropic drug administration and norepinephrine dose were lower in the levosimendan group than in the milrinone group.
40. Nanas JN, Papazoglou PP, Terrovitis JV, et al. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Am J Cardiol 2004; 94:1329-1332.
41. Tritapepe L, De Santis V, Vitale D, et al. Preconditioning effects of levosimendan in coronary artery bypass grafting: a pilot study. Br J Anaesth 2006; 96:694-700. This small but very interesting study demonstrated that a short infusion of levosimendan before coronary artery bypass grafting resulted in less myocardial damage, suggestive of a preconditioning effect. Levosimendan-treated patients had lower postoperative troponin I concentrations and a higher cardiac index than the control group.
42. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 2004; 43:2177-2182.
43. Ellger BM, Zahn PK, Van Aken HK, et al. Levosimendan: a promising treatment for myocardial stunning? Anaesthesia 2006; 61:61-63.
44. Lechner E, Moosbauer W, Pinter M, et al. Use of levosimendan, a new inodilator, for postoperative myocardial stunning in a premature neonate. Pediatr Crit Care Med 2007; 8:61-63.
45. Guarracino F, Cariello C, Danella A, et al. Effect of levosimendan on ventriculoarterial coupling in patients with ischemic cardiomyopathy. Acta Anaesthesiol Scand 2007; 51:1217-1224.
46. Rokyta R Jr, Pechman V. The effects of levosimendan on global haemodynamics in patients with cardiogenic shock. Neuroendocrinol Lett 2006; 27:121-127.
47. Tsagalou EP, Nanas JN. Resuscitation from adrenaline resistant electromechanical dissociation facilitated by levosimendan in a young man with idiopathic dilated cardiomyopathy. Resuscitation 2006; 68:147-149.
48. Delle Karth G, Buberl A, Geppert A, et al. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand 2003; 47:1251-1256.
49. Lehmann A, Lang J, Boldt J, et al. Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. Med Sci Monit 2004; 10:MT89-MT93.
50. Raja SG, Rayen BS. Levosimendan in cardiac surgery: current best available evidence. Ann Thorac Surg 2006; 81:1536-1546. This very concise review evaluates current best available evidence to assess the safety and efficacy of levosimendan usage in cardiac surgery.
51. Pollesello P, Papp Z. The cardioprotective effects of levosimendan: preclinical and clinical evidence. J Cardiovasc Pharmacol 2007; 50:257-263.
52. Tasouli A, Papadopoulos K, Antoniou T, et al. Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use. Eur J Cardiothorac Surg 2007; 32:629-633.
53. Hoefer D, Jonetzko P, Hoermann C, et al. Successful administration of levosimendan in a patient with low-gradient low-output aortic stenosis. Wien Klin Wochenschr 2006; 118:60-62.
54. Prior DL, Flaim BD, MacIsaac AI, Yii MY. Preoperative use of levosimendan in two patients with severe aortic stenosis and left ventricular dysfunction. Heart Lung Circ 2006; 15:56-58.
55. Akgul A, Mavioglu L, Katircioglu SF, et al. Levosimendan for weaning from cardiopulmonary bypass after coronary artery bypass grafting. Heart Lung Circ 2006; 15:320-324.
56. Barisin S, Husedzinovic I, Sonicki Z, et al. Levosimendan in off-pump coronary artery bypass: a four-times masked controlled study. J Cardiovasc Pharmacol 2004; 44:703-708.
57. Malliotakis P, Xenikakis T, Linardakis M, Hassoulas J. Haemodynamic effects of levosimendan for low cardiac output after cardiac surgery: a case series. Hellenic J Cardiol 2007; 48:80-88.
58. Al-Shawaf E, Ayed A, Vislocky I, et al. Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery. J Cardiothorac Vasc Anesth 2006; 20:353-357.
59. Alvarez J, Bouzada M, Fernandez AL, et al. Hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery. Rev Esp Cardiol 2006; 59:338-345.
60. Caimmi PP, Grossini E, Molinari C, et al. Intracoronary infusion of levosimendan to treat postpericardiotomy heart failure. Ann Thorac Surg 2006; 82:e33-e34.
61. Labriola C, Siro Brigiani M, Carrata F, et al. Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int J Clin Pharmacol Ther 2004; 42:204-211.
62. Ploechl W, Rajek A. The use of the novel calcium sensitizer levosimendan in critically ill patients. Anaesth Intensive Care 2004; 32:471-475.
63. Beiras-Fernandez A, Weis FC, Fuchs H, et al. Levosimendan treatment after primary organ failure in heart transplantation: a direct way to recovery? Transplantation 2006; 82:1101-1103.
64. Braun JP, Jasulaitis D, Moshirzadeh M, et al. Levosimendan may improve survival in patients requiring mechanical assist devices for postcardiotomy heart failure. Crit Care 2006; 10:R17.
65. Tokuda Y, Grant PW, Wolfenden HD, et al. Levosimendan for patients with impaired left ventricular function undergoing cardiac surgery. Interact Cardiovasc Thorac Surg 2006; 5:322-326.
66. Morelli A, Teboul JL, Maggiore SM, et al. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med 2006; 34:2287-2293.
67. Parissis JT, Paraskevaidis I, Bistola V, et al. Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am J Cardiol 2006; 98:1489-1492.
68. Kerbaul F, Rondelet B, Demester JP, et al. Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failure. Crit Care Med 2006; 34:2814-2819.
69. Missant C, Rex S, Segers P, Wouters PF. Levosimendan improves right ventriculovascular coupling in a porcine model of right ventricular dysfunction. Crit Care Med 2007; 35:707-715. In an experimental pig model of acute postischemic right ventricular dysfunction levosimendan improved global hemodynamics and optimized right ventriculovascular coupling via a moderate increase in right ventricular contractility and a mild reduction of right ventricular afterload.
70. Morais RJ. Levosimendan in severe right ventricular failure following mitral valve replacement. J Cardiothorac Vasc Anesth 2006; 20:82-84.
71. Petäjä LM, Sipponen JT, Hämmäinen PJ, et al. Levosimendan reversing low output syndrome after heart transplantation. Ann Thorac Surg 2006; 82:1529-1531.
72. Barraud D, Faivre V, Damy T, et al. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone. Crit Care Med 2007; 35:1376-1382. In endotoxin-injected rabbits treatment with levosimendan improved both systolic and diastolic functions, while milrinone or dobutamine improved only systolic function.
73. Dubin A, Murias G, Sottile JP, et al. Effects of levosimendan and dobutamine in experimental acute endotoxemia: a preliminary controlled study. Intensive Care Med 2007; 33:485-494. In an ovine model of endotoxic shock both levosimendan and dobutamine increased cardiac output and prevented the decrease in whole body oxygen delivery, but only levosimendan was able to prevent the decrease in mesenteric oxygen delivery.
74. Schwarte LA, Picker O, Bornstein SR, et al. Levosimendan is superior to milrinone and dobutamine in selectively increasing microvascular gastric mucosal oxygenation in dogs. Crit Care Med 2005; 33:135-142.
75. ATP channel opening by levosimendan in the mediation of these beneficial effects.
76. Berger R, Moertl D, Huelsmann M, et al. Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. Eur J Heart Fail 2007; 9:202-208.